Long-term results of valve replacement with the CarboMedics prosthetic heart valve.
This study examined the long-term results of the CarboMedics prosthetic heart valve. Between July 1990 and May 2000, 256 CarboMedics valve prostheses (120 single aortic, 62 single mitral, and 34 double aortic/mitral) were implanted into 216 patients (mean age 57.8 years). The mean follow-up was 57.7 +/- 36 months (maximum 133 months) with a total of 1,038.4 patient years. Patient survival, including operative deaths, was 85.1% at 10 years. Linearized rates for various complications were thromboembolism 0.39% per patient year, bleeding events 0.39% per patient year; prosthetic valve endocarditis 0.29% per patient year, nonstructural dysfunction 0.87% per patient year, and reoperation 0.39% per patient year. There were no valve thrombosis or structural valve failures in this series. The probabilities of freedom from thromboembolism and reoperation at 10 years were 96.3% and 93.1%, respectively. In conclusion, the CarboMedics valve can be used satisfactorily with a low incidence of thromboembolism and valve thrombosis.
Onoda
Koji
K
Department of Thoracic and Cardiovascular Surgery, Mie University School of Medicine, Tsu, Japan. k-onoda@clin.medic.mie-u.ac.jp
Suzuki
Tomoaki
T
Kanemitsu
Naoki
N
Yuasa
Uhito
U
Takao
Motoshi
M
Shimono
Takatsugu
T
Tanaka
Kuniyoshi
K
Shimpo
Hideto
H
Yada
Isao
I
D001021:Aortic Valve / Q000601:surgery; D006349:Heart Valve Diseases / Q000401:mortality / Q000601:surgery*; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects; D006801:Humans; D008943:Mitral Valve / Q000601:surgery; D011474:Prosthesis Design; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome